Form 4: CRISPR Therapeutics CMO Naimish Patel Reports RSU Vesting and Tax-Mandated Share Sale

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, reported the vesting of 10,000 restricted stock units and a subsequent sale of 3,932 shares to cover tax obligations.

Summary

• Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG (CRSP), acquired 10,000 common shares on May 28, 2025, through the vesting of Restricted Stock Units (RSUs).
• Following the acquisition, Mr. Patel disposed of 3,932 common shares on May 29, 2025, at a price of $35.94 per share.
• This sale was not a discretionary trade but was mandated by the Company's RSU Settlement Policy to cover tax withholding obligations related to the RSU vesting.
• After these transactions, Mr. Patel directly beneficially owns 6,068 common shares.
• An initial Restricted Stock Unit award of 40,000 common shares was granted on May 28, 2024, with quarterly vesting over four years.
• As of the filing, 30,000 Restricted Stock Units remain unvested and beneficially owned by Mr. Patel.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there's a sale of shares, it's explicitly for tax purposes and not a discretionary divestment, which mitigates negative interpretation. The underlying event is the vesting of executive compensation, which is a positive for the executive and reflects ongoing long-term incentives for management.

Positives

• The vesting of 10,000 Restricted Stock Units indicates a scheduled compensation event for the Chief Medical Officer, reflecting ongoing executive compensation.
• The remaining 30,000 unvested Restricted Stock Units provide a long-term incentive for the Chief Medical Officer, aligning his interests with shareholder value over time.

Negatives

• The sale of 3,932 shares, although mandated for tax purposes, represents a reduction in the direct shareholding of a key executive.

Future Outlook

The document outlines a future vesting schedule for the Chief Medical Officer's Restricted Stock Units, with remaining tranches vesting annually on May 28, 2026, 2027, and 2028.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of executive compensation in the form of Restricted Stock Units and a subsequent tax-mandated sale. Such transactions are common across the biotechnology and pharmaceutical industries as part of executive compensation packages designed to align management incentives with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across the biotechnology and broader corporate sectors, comparable to compensation structures at companies like Moderna, Pfizer, or Johnson & Johnson, which also utilize equity-based incentives.
• The policy requiring a mandatory sale of shares to cover tax withholding upon RSU vesting is a common and widely accepted practice, ensuring compliance with tax regulations and is seen across most publicly traded companies that grant equity compensation.

Related Party Transactions

• The acquisition of 10,000 common shares by Naimish Patel, the Chief Medical Officer, through the vesting of Restricted Stock Units, represents a transaction between an executive and the company, which is a form of related party transaction.

Stakeholder Impact

• Shareholders: The transaction is a routine executive compensation event and a tax-mandated sale, which typically has minimal direct impact on share price beyond normal market fluctuations. It confirms the ongoing alignment of executive incentives with company performance.
• Employees: The RSU vesting and tax-mandated sale illustrate the company's equity compensation practices for its executives, which can set a precedent or expectation for other employees with similar equity awards.

Next Steps

• Future tranches of the Restricted Stock Unit award are scheduled to vest on May 28, 2026, May 28, 2027, and May 28, 2028, each for 10,000 common shares.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Naimish Patel, Chief Medical Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Share Sale, Tax Withholding, Executive Compensation